当前位置: X-MOL 学术Pharmacol. Rev. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily—Update 2023
Pharmacological Reviews ( IF 21.1 ) Pub Date : 2023-11-01 , DOI: 10.1124/pharmrev.121.000436
Thomas P Burris 1 , Ian Mitchelle S de Vera 2 , Isabelle Cote 2 , Colin A Flaveny 2 , Udayanga S Wanninayake 2 , Arindam Chatterjee 2 , John K Walker 2 , Nickolas Steinauer 2 , Jinsong Zhang 2 , Laurel A Coons 2 , Kenneth S Korach 2 , Derek W Cain 2 , Anthony N Hollenberg 2 , Paul Webb 2 , Douglas Forrest 2 , Anton M Jetten 2 , Dean P Edwards 2 , Sandra L Grimm 2 , Sean Hartig 2 , Carol A Lange 2 , Jennifer K Richer 2 , Carol A Sartorius 2 , Marc Tetel 2 , Cyrielle Billon 2 , Bahaa Elgendy 2 , Lamees Hegazy 2 , Kristine Griffett 2 , Nahuel Peinetti 2 , Kerry L Burnstein 2 , Travis S Hughes 2 , Sadichha Sitaula 2 , Keitch R Stayrook 2 , Alexander Culver 2 , Meghan H Murray 2 , Brian N Finck 2 , John A Cidlowski 2
Affiliation  

The NR superfamily comprises 48 transcription factors in humans that control a plethora of gene network programs involved in a wide range of physiologic processes. This review will summarize and discuss recent progress in NR biology and drug development derived from integrating various approaches, including biophysical techniques, structural studies, and translational investigation. We also highlight how defective NR signaling results in various diseases and disorders and how NRs can be targeted for therapeutic intervention via modulation via binding to synthetic lipophilic ligands. Furthermore, we also review recent studies that improved our understanding of NR structure and signaling.

中文翻译:

国际基础与临床药理学联合会 CXIII:核受体超家族 — 2023 年更新

NR 超家族包含人类中的 48 个转录因子,它们控制着涉及广泛生理过程的大量基因网络程序。这篇综述将总结和讨论 NR 生物学和药物开发的最新进展,这些进展源自整合各种方法,包括生物物理技术、结构研究和转化研究。我们还强调了缺陷的 NR 信号传导如何导致各种疾病和病症,以及如何通过与合成亲脂性配体结合进行调节来靶向治疗干预。此外,我们还回顾了最近的研究,这些研究提高了我们对 NR 结构和信号传导的理解。
更新日期:2023-10-20
down
wechat
bug